#USA #Indianapolis #obesity #Zepbound #Eli Lilly

Introduction

In a groundbreaking study announced by Eli Lilly and Company, results show that the medication Zepbound (tirzepatide) is particularly effective in managing obesity among adults aged 55 and older. This study highlights not just the treatment's health benefits but also its potential to significantly lower healthcare costs for this demographic.

Study Overview

Conducted using data from a large cohort of 15,843 adults within the U.S. healthcare system, the study focused on individuals with a Body Mass Index (BMI) of 30 kg/m² or greater. These individuals, who had at least one weight-related health complication, began their Zepbound treatment between November 2023 and September 2025. The researchers assessed the healthcare costs associated with sustained Zepbound usage over time, comparing them with similar individuals who did not receive the medication.

Key Findings

1. Cost Reduction Over Time: The analysis found that the monthly healthcare costs for those treated with Zepbound were considerably lower than those who were untreated.
- After six months of treatment, Zepbound users experienced healthcare costs reduced by up to 15%, translating to a savings of about $181 per patient.
- At the 12-month mark, this difference grew to approximately $607 per month, culminating in an average savings of 38% compared to untreated peers.

2. Lower Hospitalization Rates: Zepbound users exhibited significantly reduced rates of hospital admissions and emergency department visits, suggesting improved health management. This is reflected by higher engagement in routine outpatient visits.

3. Financial Implications for Medicare: The analysis indicated that starting from six months, the saved healthcare costs nearly matched the monthly treatment cost of Zepbound, which is $195. By the 12-month point, the savings exceeded the treatment costs, demonstrating a strong financial incentive for both individuals and the Medicare program.

Implications for Health Policy

According to Ilya Yuffa, EVP and President of Lilly USA, this research offers solid evidence on the financial benefits of integrating obesity care within Medicare and broader health policy initiatives. As Medicare expands its coverage of GLP-1 medications like Zepbound, this study can serve as a valuable resource for policymakers, insurers, and healthcare providers.

Study Methods

The study utilized the Komodo Healthcare Map, which aggregates de-identified claims data from over 330 million individuals enrolled in U.S. health plans. All participating patients had at least a year of continuous healthcare enrollment before the study began, reinforcing the validity of the results.

Conclusion

The study emphasizes Zepbound as more than just a weight management solution; it represents a viable and cost-effective approach to addressing obesity-related healthcare costs among older adults. The significant savings potential indicates that Zepbound could play a key role in reshaping how obesity is treated and funded in the healthcare landscape. As the healthcare system grapples with the economic challenges posed by chronic health conditions like obesity, Zepbound stands out as a hopeful option, blending health benefits with economic feasibility.

About Zepbound

Zepbound is the first dual-action medication targeting GIP and GLP-1 receptors, aiming at appetite control and weight loss. It is FDA-approved for adults with obesity and those who are overweight with related health issues. Zepbound is recommended alongside a low-calorie diet and increased physical activity to achieve optimal results.